Search PubMed⌕ Search

Biomedical subjects

J Wiese

Publications and source records attributed to J Wiese.

At least 55 records · Page 3Linked to original sources

Intrauterine contraception in diabetic women.

The results of intrauterine contraception using four different types of Antigen devices in 118 insulin-treated diabetic women are reported. The patients were followed for a total of 24 months. Cumulative closure rates for the 1st year were as follows: pregnancy, 3.5; expulsion, 13.1; removal for bleeding and/or pain, 7.9; and planned pregnancy, 1.2, giving a continuation rate of 74.3. Cumulative closure rates after 24 months were as follows: pregnancy, 6.5; expulsion, 14.4; removal for bleeding and/or pain, 17.1; and planned pregnancy, 8.3, giving a continuation rate of 56.7. These results are not significantly different from those found by us in nondiabetic women, No serious side effects occurred, in particular no pelvic inflammations or perforations. Intrauterine contraception using the Antigon appears to be a well-suited method for diabetic women.

Diabetes Mellitus↗

Immediate post-partum insertion of the Antigon.

The results of intrauterine contraception using the Antigon inserted into 364 women immediately post partum are submitted. The patients were followed for 24 months, total number of woman months 5225. The follow-up was 96.7% after 3 months, 92.9% after 12 months, and 89.7% after 24 months. Four types of Antigon were used, having surface areas from 785 to 2740 mm2. Type I and the wing model (type IV), which have the smallest surface area, proved best suited. The continuation rates for types I and IV after 12 and 24 months were 77.4--59.2 and 76.4--54.5 respectively. These rates are on a level with those for Antigon inserted 6--8 weeks post partum. It is notable that the expulsion rates (12.8 and 12.7 after 12 months) were no higher than those for Antigons inserted 6--8 weeks post partum. The incidence of puerperal complications was not increased, and no perforations occurred.

Adolescent↗

Long-term contraception with norethindrone subcutaneous capsules.

Norethindrone (NET) contained in silicone rubber, for slow release, was implanted subcutaneously. The rate of release of NET was 10-12 mug/day/10 mm length of the silicone rubber. The total length of the implants used varied from 100 mm to 200 mm. During the whole observation time 562 women months, 14 a-cidental pregnancies occurred. The pregnancy rate decreased with increasing length of implants. The implants produced a transient ovulation suppression, which subsided in four to five cycles. The plasma levels of NET stabilized at a level which was less than that reached by daily oral administration of 350 mug of NET. The high pregnancy rate and the great number of implants required render the method impractical for contraception. However, the active life-span of implants is three years and because there were few minor side-effects, the method was well accepted.

Contraception↗

Ovarian function during treatment with lynoestrenol 0.5 mg daily.

Twenty-four women, all with normal ovulatory menstrual periods, were studied during in total 64 cycles on lynoestrenol 0.5 mg daily and during 11 control cycles. The 24-hour urines were collected for assay of total oestrogens on the 21st, 22nd and 23rd days of viz. the 1st, 4th, 6th and 12th cycles and for pregnanediol on the 22nd and 23rd days of the same cycles. Oestrogen excretion was at the same level during treatment and control cycles. All the control cycles and 9 and 14 % respectively of the treatment cycles were ovulatory judging by the plasma progesterone and the pregnanediol excretion. On the basis of the latter parameter there was a certain luteal activity during 36 % of the treatment cycles. In all cycles but one, however, the plasma progesterone and the pregnanediol excretion were lower than during the control cycles. It must be assumed, therefore, that lynoestrenol in a dose of 0.5 mg daily inhibits the ovulation or function of the corpora lutea in practically all cases.

Adult↗